<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Studies show that blocking the activation of caspases by the caspase inhibitors z-VAD.FMK and z-DEVD.FMK can reduce ischemic neuronal injury after <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Because the severity of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> was mild in some studies, we tested the efficacy of these caspase inhibitors on moderately severe but transient forebrain and focal ischemic insults in the rat </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Various regimens of z-VAD, z-DEVD, and control DMSO were given to rats subjected to either 4-vessel occlusion <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> (4-VO, 10-minute occlusion, 7-day survival) or distal middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAo, 90-minute occlusion, 22.5-hour survival) </plain></SENT>
<SENT sid="3" pm="."><plain>In global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, treatments were given immediately after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> (experiment 1) or as preischemic and postischemic treatments (experiment 2) </plain></SENT>
<SENT sid="4" pm="."><plain>Three focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> experiments were done </plain></SENT>
<SENT sid="5" pm="."><plain>Injection times were 60 minutes into <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> (experiment 1) and 60 minutes into <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> plus 30 and 120 minutes after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> (experiment 2) </plain></SENT>
<SENT sid="6" pm="."><plain>Experiment 3 was identical to experiment 2 except that a 30-minute preischemia treatment was instituted </plain></SENT>
<SENT sid="7" pm="."><plain>Core normothermia was maintained in <z:hpo ids='HP_0000001'>all</z:hpo> experiments during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>However, in the last focal and global experiments, core and brain temperatures, respectively, were also measured after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> with telemetry probes </plain></SENT>
<SENT sid="9" pm="."><plain>Because <z:hpo ids='HP_0001945'>hyperthermia</z:hpo> accompanied z-DEVD treatment, an extra z-DEVD-treated group (MCAo) was included with temperature clamped at normothermia </plain></SENT>
<SENT sid="10" pm="."><plain>RESULTS: Neither z-VAD nor z-DEVD significantly reduced CA1 injury after global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>In focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, both drugs significantly reduced infarction, but only in the third experiment, and the prevention of <z:hpo ids='HP_0001945'>hyperthermia</z:hpo> that accompanied z-DEVD treatment did not alter this </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: These results suggest a detrimental role of caspases in moderately severe focal but not global <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
</text></document>